Search for "primary amine" in Full Text gives 158 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2013, 9, 155–165, doi:10.3762/bjoc.9.18
Graphical Abstract
Scheme 1: Activation of amine-bonded Michael acceptors by protonation versus Lewis acid interaction.
Scheme 2: Synthesis of 4-hydroxycoumarin derivatives by Michael addition [19-27].
Scheme 3: Precatalysts 5–8 and synthesis from chiral 1,2-diamines and 2-sulfobenzoic anhydrides.
Figure 1: X-ray crystallographic structure of 5. The conformation of the 2-sulfobenzoic moiety is fixed by hy...
Figure 2: Michael acceptors employed as substrates in the nucleophilic addition of 4-hydroxycoumarin (1).
Scheme 4: Computationally analyzed pathways A (C-protonation), and B (N-protonation), arising from the additi...
Scheme 5: Computed energy profile for reaction path A (C-protonation) and B (N-protonation) corresponding to ...
Figure 3: Enantio-determining transition states arising from the addition of 4-hydroxycoumarin to cyclohexeno...
Figure 4: The competing enantio-determining transition structures TS-14a and TS-14g. The reason for the desta...
Beilstein J. Org. Chem. 2013, 9, 56–63, doi:10.3762/bjoc.9.7
Graphical Abstract
Figure 1: Azidosugars used in this study. The synthesis of the azidosugars 1–3 was modified from [47,48], compounds 4...
Scheme 1: Reaction conditions and reagents: (a) Ns-chloride (6.00 equiv), 2,4,6-collidine (12.0 equiv), CH2Cl2...
Scheme 2: Synthesis of spermine conjugates 20,21 and 24,25. 2-chlorotrityl chloride resin was used as a solid...
Scheme 3: Synthesis of hexaalkynyl peptoids 26 and 27 on solid supports.
Scheme 4: Synthesis of a hexa-glycosylated peptoid 28.
Beilstein J. Org. Chem. 2012, 8, 2214–2222, doi:10.3762/bjoc.8.250
Graphical Abstract
Scheme 1: Strategy for the synthesis of (1,4-dihydro)pyridines by deprotonation/intramolecular carbolithiatio...
Scheme 2: Feasibility of the deprotonation/intramolecular carbolithiation.
Scheme 3: Synthesis of the starting N-allyl-ynamides.
Scheme 4: Intramolecular carbolithiation of N-allyl-ynamides to 1,4-dihydropyridines and pyridines.
Scheme 5: 2,3-Disubstituted pyridines by trapping of the intermediate metallated 1,4-dihydropyridine.
Scheme 6: Formal synthesis of the anti-dyskinesia agent, 5-HT1A receptor agonist, dopamine D2 receptor ligand...
Beilstein J. Org. Chem. 2012, 8, 2072–2084, doi:10.3762/bjoc.8.233
Graphical Abstract
Figure 1: Chemical structure of phalloidin with the attachment site (R) used for conjugation to uptake-mediat...
Figure 2: Cytotoxicity of phalloidin derivatives. NIH 3T3 mouse fibroblasts were incubated with various conce...
Figure 3: n-Octanol/water distribution coefficients (log Pow) of the hydrophobic phalloidin derivatives of Figure 2 p...
Figure 4: (a) and (b): NIH 3T3 mouse fibroblasts were incubated with various concentrations of phalloidin and...
Figure 5: Time course of uptake in NIH 3T3 cells of three phalloidin derivatives as measured by the cytotoxic...
Figure 6: (a) Chemical structure of tetramethylrhodaminyl-phalloidin (3). (b) Growth inhibition of NIH 3T3 mo...
Figure 7: Chemical structure of amanitin with attachment site for conjugation to internalization-mediating mo...
Figure 8: NIH 3T3 mouse fibroblasts were incubated with various concentrations of α-amanitin and amanitin der...
Beilstein J. Org. Chem. 2012, 8, 2004–2018, doi:10.3762/bjoc.8.227
Graphical Abstract
Figure 1: Representative drug candidates of amino-azaindole and phenyl-azaindole containing motifs.
Scheme 1: Cross coupling of 4-bromo-7-azaindole with amides, amines, amino acid esters and phenols.
Beilstein J. Org. Chem. 2012, 8, 1839–1843, doi:10.3762/bjoc.8.211
Graphical Abstract
Scheme 1: Synthesis of polysubstituted tetrahydroquinolines 1a–1m.
Figure 1: Molecular structure of compound 1c.
Scheme 2: The proposed mechanism of domino Povarov reaction.
Beilstein J. Org. Chem. 2012, 8, 1485–1498, doi:10.3762/bjoc.8.168
Graphical Abstract
Scheme 1: Synthesis of guanidine-thiourea organocatalyst 7.
Scheme 2: Henry reaction of 3-phenylpropionaldehyde (8) with nitromethane (9).
Scheme 3: Michael addition of (12) and (14) to trans-β-nitrostyrene (11).
Figure 1: Optimized geometries of four conformers of catalyst 7. Energies are in kcal·mol−1, B3PW91/6–31G(d) ...
Scheme 4: Energy profile for the first step of the reaction between catalyst 7 and malonate 14. Energies are ...
Figure 2: Complexes (CatN1–CatN5) between catalyst 7 and nitrostyrene 11. Energies are in kcal·mol−1, B3PW91/...
Scheme 5: Two possible routes for ternary complex formation. Energies are in kcal·mol−1, B3PW91/6–31G(d) (fir...
Figure 3: Geometries of transition states for R and S products. Relative energies (with respect to Init10) ar...
Figure 4: Geometries of transition states for R and S products. Relative energies (with respect to Init10) ar...
Figure 5: B3PW91/6–31G(d) (first entry), DFT-PCM (second entry), MP2/6–31G(d)//B3PW91/6–31G(d) (third entry) ...
Figure 6: Geometries of transition states for R and S products with 7-TABD catalyst. Relative energies (to In...
Beilstein J. Org. Chem. 2012, 8, 1452–1457, doi:10.3762/bjoc.8.165
Graphical Abstract
Figure 1: The conjugated addition to unsaturated 1,4-diketone 1.
Figure 2: Organocatalysts screened.
Figure 3: Proposed transition state.
Figure 4: Calculated (red) and experimental (blue) IR (A) and VCD spectrum (B) of compound (R)-3a.
Beilstein J. Org. Chem. 2012, 8, 1443–1451, doi:10.3762/bjoc.8.164
Graphical Abstract
Figure 1: General structure of sulfoximines 1 and one of the enantiomers of S-methyl-S-phenylsulfoximine ((S)-...
Figure 2: Structures of chiral mono- and bifunctional (bis-)thioureas that have been used as organocatalysts.
Scheme 1: Synthesis of compound (S)-3.
Scheme 2: Organocatalytic desymmetrization of the cyclic anhydride 4 with (S)-3.
Scheme 3: Attempted synthesis of sulfonimidoyl-substituted thiourea (R)-9.
Scheme 4: Synthesis of the sulfonimidoyl-containing thioureas (S)-12 and (S)-13.
Scheme 5: Syntheses of ethylene-linked sulfonimidoyl-containing thioureas (SS,SC)-18 and (RS,SC)-19.
Beilstein J. Org. Chem. 2012, 8, 1126–1133, doi:10.3762/bjoc.8.125
Graphical Abstract
Figure 1: Thiol, alkene and organocatalyst building blocks for combined bead polymerization and Cinchona orga...
Scheme 1: Combined bead polymerization and Cinchona organocatalyst immobilization by thiol–ene addition.
Beilstein J. Org. Chem. 2012, 8, 441–447, doi:10.3762/bjoc.8.50
Graphical Abstract
Scheme 1: 2,6-Dihydropyridine-3,5-dicarboxylates as useful organic dyads.
Scheme 2: Synthesis of dihydropyridine derivatives from enaminones.
Scheme 3: Dihydropyridine derivatives 4–7 and enaminone 8.
Figure 1: ORTEP of compounds 4b, 6d, 6f and 7a.
Figure 2: Absorption spectra of compounds 2j, 6a–f and 7a,b in acetonitrile (1 × 10−4 M).
Figure 3: Emission spectra of compounds 4a, 6a–f and 7a,b after excitation at their absorption λmax in the ra...
Figure 4: Emission spectra of compounds 2j, 4a, 6a–f and 7a,b after excitation at their absorption λmax in th...
Scheme 4: Synthesis of dihydropyridines from an enamino aldehyde, an enamino ester and an enaminonitrile.
Scheme 5: Nitric acid oxidation of dihydropyridines 2a–c and 6a.
Figure 5: ORTEP of compound 15d.
Beilstein J. Org. Chem. 2011, 7, 1622–1635, doi:10.3762/bjoc.7.191
Graphical Abstract
Figure 1: Cyanobacteria proliferate in diverse habitats. A) Bloom-forming freshwater cyanobacteria of the gen...
Figure 2: Schematic representation of enzymatic domains in A) nonribosomal peptide synthetases (NRPS); B) pol...
Figure 3: Structures of NRPS and PKS products in freshwater cyanobacteria.
Figure 4: A) Synthesis of the Adda ((2S,3S,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl-4,6-decadienoic...
Figure 5: Structures of NRPS and PKS products in marine cyanobacteria.
Figure 6: A) Formation of the trichloroleucyl starter unit of barbamide (7) synthesis through the non-heme ir...
Figure 7: Structures of NRPS and PKS products in terrestrial cyanobacteria.
Figure 8: Synthesis of the (2S,4S)-4-methylproline moiety of nostopeptolides A (13).
Figure 9: Structures of cyanobacterial peptides that are synthesized ribosomally and post-translationally mod...
Figure 10: Formation of ester linkages and ω-amide linkage in microviridins 17 by the ATP grasp ligases MvdD a...
Figure 11: Structures of cyanobacterial sunscreen compounds.
Beilstein J. Org. Chem. 2011, 7, 1577–1583, doi:10.3762/bjoc.7.186
Graphical Abstract
Scheme 1: Synthesis of functionalized phenols. Reagents and conditions: a) Boc2O, 1.0 equiv, THF, 0 °C → rt, ...
Scheme 2: Single substitution of hexachlorocyclotriphosphazene. Reagents and conditions: a) Cs2CO3, 1.67 equi...
Scheme 3: Synthesis of dansylated dendrons. Reagents and conditions: a) Cs2CO3, 11 equiv, THF, rt, 48 h. b) Cs...
Scheme 4: Synthesis of dabsylated dendrons. Reagents and conditions: a) Cs2CO3, 11 equiv, THF, rt, 48 h. b) T...
Figure 1: UV–vis spectra of compounds 8–10.
Figure 2: UV–vis spectra of compounds 4, 11 and 12 in dioxane.
Figure 3: Excitation (left) and emission (right) spectra of compounds 8–10 in 1,4-dioxane (the excitation spe...
Figure 4: Emission spectra (λexc = 347 nm) of compound 10 in mixtures water/dioxane with different molar frac...
Figure 5: λem,max of 10 in mixture water/dioxane vs molar fraction of water in dioxane (filled squares) and v...
Beilstein J. Org. Chem. 2011, 7, 1387–1406, doi:10.3762/bjoc.7.163
Graphical Abstract
Scheme 1: Synthesis of substituted amides.
Scheme 2: Synthesis of ketocarbamates and imidazolones.
Scheme 3: Access to β-lactams.
Scheme 4: Access to β-lactams with increased structural diversity.
Scheme 5: Synthesis of imidazolinium salts.
Scheme 6: Access to the indenamine core.
Scheme 7: Synthesis of substituted tetrahydropyridines.
Scheme 8: Synthesis of more substituted tetrahydropyridines.
Scheme 9: Synthesis of chiral tetrahydropyridines.
Scheme 10: Preparation of α-aminonitrile by a catalyzed Strecker reaction.
Scheme 11: Synthesis of spiroacetals.
Scheme 12: Synthesis of masked 3-aminoindan-1-ones.
Scheme 13: Synthesis of homoallylic amines and α-aminoesters.
Scheme 14: Preparation of 1,2-dihydroisoquinolin-1-ylphosphonates.
Scheme 15: Pyrazole elaboration by cycloaddition of hydrazines with alkynones generated in situ.
Scheme 16: An alternative approach to pyrazoles involving hydrazine cycloaddition.
Scheme 17: Synthesis of pyrroles by cyclization of propargyl amines.
Scheme 18: Isoindolone and phthalazone synthesis by cyclization of acylhydrazides.
Scheme 19: Sultam synthesis by cyclization of sulfonamides.
Scheme 20: Synthesis of sulfonamides by aminosulfonylation of aryl iodides.
Scheme 21: Pyrrolidine synthesis by carbopalladation of allylamines.
Scheme 22: Synthesis of indoles through a sequential C–C coupling/desilylation–coupling/cyclization reaction.
Scheme 23: Synthesis of indoles by a site selective Pd/C catalyzed cross-coupling approach.
Scheme 24: Synthesis of isoindolin-1-one derivatives through a sequential Sonogashira coupling/carbonylation/h...
Scheme 25: Synthesis of pyrroles through an allylic amination/Sonogashira coupling/hydroamination reaction.
Scheme 26: Synthesis of indoles through a Sonogashira coupling/cyclofunctionalization reaction.
Scheme 27: Synthesis of indoles through a one-pot two-step Sonogashira coupling/cyclofunctionalization reactio...
Scheme 28: Synthesis of α-alkynylindoles through a Pd-catalyzed Sonogashira/double C–N coupling reaction.
Scheme 29: Synthesis of indoles through a Pd-catalyzed sequential alkenyl amination/C-arylation/N-arylation.
Scheme 30: Synthesis of N-aryl-2-benzylpyrrolidines through a sequential N-arylation/carboamination reaction.
Scheme 31: Synthesis of phenothiazine derivatives through a one-pot palladium-catalyzed double C–N arylation i...
Scheme 32: Synthesis of substituted imidazolidinones through a palladium-catalyzed three-component reaction of...
Scheme 33: Synthesis of 2,3-diarylated amines through a palladium-catalyzed four-component reaction involving ...
Scheme 34: Synthesis of rolipram involving a Pd-catalyzed three-component reaction.
Scheme 35: Synthesis of seven-membered ring lactams through a Pd-catalyzed amination/intramolecular cyclocarbo...
Beilstein J. Org. Chem. 2011, 7, 1299–1303, doi:10.3762/bjoc.7.151
Graphical Abstract
Scheme 1: Passerini reactions of α,β-unsaturated aldehyde 5.
Scheme 2: Passerini and Ugi reaction of saturated aldehyde 7.
Beilstein J. Org. Chem. 2011, 7, 1095–1099, doi:10.3762/bjoc.7.125
Graphical Abstract
Scheme 1: Reductive amination with zinc in aqueous base solution.
Beilstein J. Org. Chem. 2011, 7, 824–830, doi:10.3762/bjoc.7.94
Graphical Abstract
Scheme 1: One-pot hydrozirconation-reductive coupling of allene 2 and nitrile 7.
Scheme 2: Cyclization of allenylnitrile 18.
Figure 1: Coupling constant analysis of the Boc-protected aminopyran ring in 21.
Scheme 3: Proposed chelated transition state model.
Scheme 4: Conversion of homoallylic amines to β-amino acid derivatives.
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Beilstein J. Org. Chem. 2011, 7, 59–74, doi:10.3762/bjoc.7.10
Graphical Abstract
Scheme 1: Synthesis of selective D3 receptor ligands.
Scheme 2: Synthesis of a novel 5-HT1B receptor antagonist.
Scheme 3: Synthesis of A-366833, a selective α4β2 neural nicotinic receptor agonist.
Scheme 4: A new route to oxcarbazepine.
Scheme 5: Synthesis of key intermediates for norepinephrine transporter (NET) inhibitors.
Scheme 6: N-Annulation yielding substituted indole for the synthesis of demethylasterriquinone A1.
Scheme 7: Palladium-catalysed double N-arylation contributing to the synthesis of murrazoline.
Scheme 8: Synthesis of vitamin E amines.
Scheme 9: Improved synthesis of martinellic acid.
Scheme 10: New tariquidar-derived ABCB1 inhibitors.
Scheme 11: β-Carbolin-1-ones as inhibitors of tumour cell proliferation.
Scheme 12: Copper-catalysed synthesis of promazine drugs.
Scheme 13: Palladium-catalysed multicomponent reaction for the synthesis of promazine drugs.
Scheme 14: Key intermediate for imatinib.
Scheme 15: Synthesis of an effective Chek1/KDR kinase inhibitor.
Scheme 16: Macrocyclization as final step of the synthesis of heat shock protein inhibitor.
Scheme 17: Synthesis of N-arylimidazoles.
Scheme 18: Synthesis of benzolactam V8.
Scheme 19: Synthesis of an intermediate for lotrafiban (SB-214857).
Scheme 20: Intermolecular effort towards lotrafiban.
Scheme 21: Synthesis of matrix metalloproteases (MMPs) inhibitor.
Scheme 22: Regioselective 9-N-arylation of purines.
Scheme 23: N-Arylation of adenine and cytosine.
Scheme 24: 9-N-Arylpurines as enterovirus inhibitors.
Scheme 25: Xanthine analogues as kinase inhibitors.
Scheme 26: Synthesis of dual PPARα/γ agonists.
Scheme 27: N-Aryltriazole ribonucleosides with anti-proliferative activity.
Beilstein J. Org. Chem. 2010, 6, 922–931, doi:10.3762/bjoc.6.98
Graphical Abstract
Scheme 1: Synthesis of magnetic biocatalyst particles.
Figure 1: Structures of comonomers employed in the synthesis of functional core–shell particles.
Figure 2: TEM images of a) Fe3O4 nanoparticles electrostatically stabilized by citric acid; b) Fe3O4@P(M100) ...
Figure 3: a) Cloud point temperature Tc of Fe3O4@P(OxMy) in water in relation to molar fraction of MEMA χM,ex...
Figure 4: a) Normalized magnetization loops of dispersions based on Fe3O4@CA in water (solid line), Fe3O4@CPS...
Scheme 2:
Reaction scheme of the enzymatic digestion of BAPNA catalyzed by magnetically labeled trypsin ().
Figure 5: a) Cornish-Bowden diagram for the temperature-dependent kinetic data of trypsin activity, and b) Ea...
Scheme 3: Proposed mechanism of catalytic activity after heating magnetic biocatalyst particles above Tc.
Figure 6: a) Turnover number kcat and b) Michaelis constant Km of particle- immobilized trypsin vs free tryps...
Beilstein J. Org. Chem. 2010, 6, No. 32, doi:10.3762/bjoc.6.32
Graphical Abstract
Figure 1: Biologically important amines and quaternary ammonium salts: histamine (1), dopamine (2) and acetyl...
Figure 2: Crown ether 18-crown-6.
Figure 3: Conformations of 18-crown-6 (4) in solvents of different polarity.
Figure 4: Binding topologies of the ammonium ion depending on the crown ring size.
Figure 5: A “pseudorotaxane” structure consisting of 24-crown-8 and a secondary ammonium ion (5); R = Ph.
Figure 6: Typical examples of azacrown ethers, cryptands and related aza macrocycles.
Figure 7: Binding of ammonium to azacrown ethers and cryptands [111-113].
Figure 8: A 19-crown-6-ether with decalino blocking groups (11) and a thiazole-dibenzo-18-crown-6-ether (12).
Figure 9: 1,3-Bis(6-oxopyridazin-1-yl)propane derivatives 13 and 14 by Campayo et al.
Figure 10: Fluorescent azacrown-PET-sensors based on coumarin.
Figure 11: Two different pyridino-cryptands (17 and 18) compared to a pyridino-crown (19); chiral ammonium ion...
Figure 12: Pyridino-18-crown-6 ligand (21), a similar acridino-18-crown-6 ligand (22) and a structurally relat...
Figure 13: Ciral pyridine-azacrown ether receptors 24.
Figure 14: Chiral 15-crown-5 receptors 26 and an analogue 18-crown-6 ligand 27 derived from amino alcohols.
Figure 15: C2-symmetric chiral 18-crown-6 amino alcohol derivatives 28 and related macrocycles.
Figure 16: Macrocycles with diamide-diester groups (30).
Figure 17: C2-symmetric chiral aza-18-crown-6 ethers (31) with phenethylamine residues.
Figure 18: Chiral C-pivot p-methoxy-phenoxy-lariat ethers.
Figure 19: Chiral lariat crown ether 34.
Figure 20: Sucrose-based chiral crown ether receptors 36.
Figure 21: Permethylated fructooligosaccharide 37 showing induced-fit chiral recognition.
Figure 22: Biphenanthryl-18-crown-6 derivative 38.
Figure 23: Chiral lariat crown ethers derived from binol by Fuji et al.
Figure 24: Chiral phenolic crown ether 41 with “aryl chiral barriers” and guest amines.
Figure 25: Chiral bis-crown receptor 43 with a meso-ternaphthalene backbone.
Figure 26: Chromogenic pH-dependent bis-crown chemosensor 44 for diamines.
Figure 27: Triamine guests for binding to receptor 44.
Figure 28: Chiral bis-crown phenolphthalein chemosensors 46.
Figure 29: Crown ether amino acid 47.
Figure 30: Luminescent receptor 48 for bis-alkylammonium guests.
Figure 31: Luminescent CEAA (49a), a bis-CEAA receptor for amino acids (49b) and the structure of lysine bindi...
Figure 32: Luminescent CEAA tripeptide for binding small peptides.
Figure 33: Bis crown ether 51a self assembles co-operatively with C60-ammonium ion 51b.
Figure 34: Triptycene-based macrotricyclic dibenzo-[24]-crown-8 ether host 52 and guests.
Figure 35: Copper imido diacetic acid azacrown receptor 53a and the suggested His-Lys binding motif; a copper ...
Figure 36: Urea (54) and thiourea (55) benzo crown receptor for transport and extraction of amino acids.
Figure 37: Crown pyryliums ion receptors 56 for amino acids.
Figure 38: Ditopic sulfonamide bridged crown ether receptor 57.
Figure 39: Luminescent peptide receptor 58.
Figure 40: Luminescent receptor 59 for the detection of D-glucosamine hydrochloride in water/ethanol and lumin...
Figure 41: Guanidinium azacrown receptor 61 for simple amino acids and ditopic receptor 62 with crown ether an...
Figure 42: Chiral bicyclic guanidinium azacrown receptor 63 and similar receptor 64 for the enantioselective t...
Figure 43: Receptors for zwitterionic species based on luminescent CEAAs.
Figure 44: 1,10-Azacrown ethers with sugar podand arms and the anticancer agent busulfan.
Figure 45: Benzo-18-crown-6 modified β-cyclodextrin 69 and β-cyclodextrin functionalized with diaza-18-crown-6...
Figure 46: Receptors for colorimetric detection of primary and secondary ammonium ions.
Figure 47: Porphyrine-crown-receptors 72.
Figure 48: Porphyrin-crown ether conjugate 73 and fullerene-ammonium ion guest 74.
Figure 49: Calix[4]arene (75a), homooxocalix[4]arene (75b) and resorcin[4]arene (75c) compared (R = H, alkyl c...
Figure 50: Calix[4]arene and ammonium ion guest (R = H, alkyl, OAcyl etc.), possible binding sites; A: co-ordi...
Figure 51: Typical guests for studies with calixarenes and related molecules.
Figure 52: Lower rim modified p-tert-butylcalix[5]arenes 82.
Figure 53: The first example of a water soluble calixarene.
Figure 54: Sulfonated water soluble calix[n]arenes that bind ammonium ions.
Figure 55: Displacement assay for acetylcholine (3) with a sulfonato-calix[6]arene (84b).
Figure 56: Amino acid inclusion in p-sulfonatocalix[4]arene (84a).
Figure 57: Calixarene receptor family 86 with upper and lower rim functionalization.
Figure 58: Calix[6]arenes 87 with one carboxylic acid functionality.
Figure 59: Sulfonated calix[n]arenes with mono-substitution at the lower rim systematically studied on their r...
Figure 60: Cyclotetrachromotropylene host (91) and its binding to lysine (81c).
Figure 61: Calixarenes 92 and 93 with phosphonic acids groups.
Figure 62: Calix[4]arene tetraphosphonic acid (94a) and a double bridged analogue (94b).
Figure 63: Calix[4]arene tetraphosphonic acid ester (92c) for surface recognition experiments.
Figure 64: Calixarene receptors 95 with α-aminophosphonate groups.
Figure 65: A bridged homocalix[3]arene 95 and a distally bridged homocalix[4]crown 96.
Figure 66: Homocalix[3]arene ammonium ion receptor 97a and the Reichardt’s dye (97b) for colorimetric assays.
Figure 67: Chromogenic diazo-bridged calix[4]arene 98.
Figure 68: Calixarene receptor 99 by Huang et al.
Figure 69: Calixarenes 100 reported by Parisi et al.
Figure 70: Guest molecules for inclusion in calixarenes 100: DAP × 2 HCl (101a), APA (101b) and Lys-OMe × 2 HC...
Figure 71: Different N-linked peptido-calixarenes open and with glycol chain bridges.
Figure 72: (S)-1,1′-Bi-2-naphthol calixarene derivative 104 published by Kubo et al.
Figure 73: A chiral ammonium-ion receptor 105 based on the calix[4]arene skeleton.
Figure 74: R-/S-phenylalaninol functionalized calix[6]arenes 106a and 106b.
Figure 75: Capped homocalix[3]arene ammonium ion receptor 107.
Figure 76: Two C3 symmetric capped calix[6]arenes 108 and 109.
Figure 77: Phosphorous-containing rigidified calix[6]arene 110.
Figure 78: Calix[6]azacryptand 111.
Figure 79: Further substituted calix[6]azacryptands 112.
Figure 80: Resorcin[4]arene (75c) and the cavitands (113).
Figure 81: Tetrasulfonatomethylcalix[4]resorcinarene (114).
Figure 82: Resorcin[4]arenes (115a/b) and pyrogallo[4]arenes (115c, 116).
Figure 83: Displacement assay for acetylcholine (3) with tetracyanoresorcin[4]arene (117).
Figure 84: Tetramethoxy resorcinarene mono-crown-5 (118).
Figure 85: Components of a resorcinarene based displacement assay for ammonium ions.
Figure 86: Chiral basket resorcin[4]arenas 121.
Figure 87: Resorcinarenes with deeper cavitand structure (122).
Figure 88: Resorcinarene with partially open deeper cavitand structure (123).
Figure 89: Water-stabilized deep cavitands with partially structure (124, 125).
Figure 90: Charged cavitands 126 for tetralkylammonium ions.
Figure 91: Ditopic calix[4]arene receptor 127 capped with glycol chains.
Figure 92: A calix[5]arene dimer for diammonium salt recognition.
Figure 93: Calixarene parts 92c and 129 for the formation molecular capsules.
Figure 94: Encapsulation of a quaternary ammonium cation by two resorcin[4]arene molecules (NMe4+@[75c]2 × Cl−...
Figure 95: Encapsulation of a quaternary ammonium cation by six resorcin[4]arene molecules (NMe3D+@[130]6 × Cl−...
Figure 96: Structure and schematic of cucurbit[6]uril (CB[6], 131a).
Figure 97: Cyclohexanocucurbit[6]uril (CB′[6], 132) and the guest molecule spermine (133).
Figure 98: α,α,δ,δ-Tetramethylcucurbit[6]uril (134).
Figure 99: Structure of the cucurbituril-phthalhydrazide analogue 135.
Figure 100: Organic cavities for the displacement assay for amine differentiation.
Figure 101: Displacement assay methodology for diammonium- and related guests involving cucurbiturils and some ...
Figure 102: Nor-seco-Cucurbituril (±)-bis-ns-CB[6] (140) and guest molecules.
Figure 103: The cucurbit[6]uril based complexes 141 for chiral discrimination.
Figure 104: Cucurbit[7]uril (131c) and its ferrocene guests (142) opposed.
Figure 105: Cucurbit[7]uril (131c) guest inclusion and representative guests.
Figure 106: Cucurbit[7]uril (131c) binding to succinylcholine (145) and different bis-ammonium and bis-phosphon...
Figure 107: Paraquat-cucurbit[8]uril complex 149.
Figure 108: Gluconuril-based ammonium receptors 150.
Figure 109: Examples of clefts (151a), tweezers (151b, 151c, 151d) and clips (151e).
Figure 110: Kemp’s triacid (152a), on example of Rebek’s receptors (152b) and guests.
Figure 111: Amino acid receptor (154) by Rebek et al.
Figure 112: Hexagonal lattice designed hosts by Bell et al.
Figure 113: Bell’s amidinium receptor (156) and the amidinium ion (157).
Figure 114: Aromatic phosphonic acids.
Figure 115: Xylene phosphonates 159 and 160a/b for recognition of amines and amino alcohols.
Figure 116: Bisphosphonate recognition motif 161 for a colorimetric assay with alizarin complexone (163) for ca...
Figure 117: Bisphosphonate/phosphate clip 164 and bisphosphonate cleft 165.
Figure 118: N-Methylpyrazine 166a, N-methylnicotinamide iodide (166b) and NAD+ (166c).
Figure 119: Bisphosphate cavitands.
Figure 120: Bisphosphonate 167 of Schrader and Finocchiaro.
Figure 121: Tweezer 168 for noradrenaline (80b).
Figure 122: Different tripods and heparin (170).
Figure 123: Squaramide based receptors 172.
Figure 124: Cage like NH4+ receptor 173 of Kim et al.
Figure 125: Ammonium receptors 174 of Chin et al.
Figure 126: 2-Oxazolin-based ammonium receptors 175a–d and 176 by Ahn et al.
Figure 127: Racemic guest molecules 177.
Figure 128: Tripods based on a imidazole containing macrocycle (178) and the guest molecules employed in the st...
Figure 129: Ammonium ion receptor 180.
Figure 130: Tetraoxa[3.3.3.3]paracyclophanes 181 and a cyclophanic tetraester (182).
Figure 131: Peptidic bridged paraquat-cyclophane.
Figure 132: Shape-selective noradrenaline host.
Figure 133: Receptor 185 for binding of noradrenaline on surface layers from Schrader et al.
Figure 134: Tetraphosphonate receptor for binding of noradrenaline.
Figure 135: Tetraphosphonate 187 of Schrader and Finocchiaro.
Figure 136: Zinc-Porphyrin ammonium-ion receptors 188 and 189 of Mizutani et al.
Figure 137: Zinc porphyrin receptor 190.
Figure 138: Zinc porphyrin receptors 191 capable of amino acid binding.
Figure 139: Zinc-porphyrins with amino acid side chains for stereoinduction.
Figure 140: Bis-zinc-bis-porphyrin based on Tröger’s base 193.
Figure 141: BINAP-zinc-prophyrin derivative 194 and it’s guests.
Figure 142: Bisaryl-linked-zinc-porphyrin receptors.
Figure 143: Bis-zinc-porphyrin 199 for diamine recognition and guests.
Figure 144: Bis-zinc-porphyrin crown ether 201.
Figure 145: Bis-zinc-porphyrin 202 for stereodiscrimination (L = large substituent; S = small substituent).
Figure 146: Bis-zinc-porphyrin[3]rotaxane and its copper complex and guests.
Figure 147: Dien-bipyridyl ligand 206 for co-ordination of two metal atoms.
Figure 148: The ligand and corresponding tetradentate co-complex 207 serving as enantioselective receptor for a...
Figure 149: Bis(oxazoline)–copper(II) complex 208 for the recognition of amino acids in aqueous solution.
Figure 150: Zinc-salen-complexes 209 for the recognition tertiary amines.
Figure 151: Bis(oxazoline)–copper(II) 211 for the recognition of amino acids in aqueous solution.
Figure 152: Zn(II)-complex of a C2 terpyridine crown ether.
Figure 153: Displacement assay and receptor for aspartate over glutamate.
Figure 154: Chiral complex 214 for a colorimetric displacement assay for amino acids.
Figure 155: Metal complex receptor 215 with tripeptide side arms.
Figure 156: A sandwich complex 216 and its displaceable dye 217.
Figure 157: Lanthanide complexes 218–220 for amino acid recognition.
Figure 158: Nonactin (221), valinomycin (222) and vancomycin (223).
Figure 159: Monesin (224a) and a chiral analogue for enantiodiscrimination of ammonium guests (224b).
Figure 160: Chiral podands (226) compared to pentaglyme-dimethylether (225) and 18-crown-6 (4).
Figure 161: Lasalocid A (228).
Figure 162: Lasalocid derivatives (230) of Sessler et al.
Figure 163: The Coporphyrin I tetraanion (231).
Figure 164: Linear and cyclic peptides for ammonium ion recognition.
Figure 165: Cyclic and bicyclic depsipeptides for ammonium ion recognition.
Figure 166: α-Cyclodextrin (136a) and novocaine (236).
Figure 167: Helical diol receptor 237 by Reetz and Sostmann.
Figure 168: Ammonium binding spherand by Cram et al. (238a) and the cyclic[6]metaphenylacetylene 238b in compar...
Figure 169: Receptor for peptide backbone and ammonium binding (239).
Figure 170: Anion sensor principle with 3-hydroxy-2-naphthanilide of Jiang et al.
Figure 171: 7-bromo-3-hydroxy-N-(2-hydroxyphenyl)naphthalene 2-carboxamide (241) and its amine binding.
Figure 172: Naturally occurring catechins with affinity to quaternary ammonium ions.
Figure 173: Spiropyran (244) and merocyanine form (244a) of the amino acid receptors of Fuji et al.
Figure 174: Coumarin aldehyde (245) and its iminium species with amino acid bound (245a) by Glass et al.
Figure 175: Coumarin aldehyde appended with boronic acid.
Figure 176: Quinolone aldehyde dimers by Glass et al.
Figure 177: Chromogenic ammonium ion receptors with trifluoroacetophenone recognition motifs.
Figure 178: Chromogenic ammonium ion receptor with trifluoroacetophenone recognition motif bound on different m...
Beilstein J. Org. Chem. 2010, 6, No. 21, doi:10.3762/bjoc.6.21
Graphical Abstract
Figure 1: Typical representatives of iminosugars.
Figure 2: N-Modified iminosugars 5–9 as potential pharmacological chaperones.
Figure 3: Structure of NOEV 10.
Scheme 1: Three-step-synthesis of partially protected 1-deoxy-D-galactonojirimycin derivative 12 from 10 via ...
Scheme 2: Synthesis of N-(6-aminohexyl)-1-deoxygalactonojirimycin (15) from 12 via 14.
Scheme 3: Synthesis of lipophilic 1-deoxy-D-galactonojirimycin derivatives 16–18 by chemoselective acylation ...
Scheme 4: Synthesis of compounds 19 as well as 20 from primary amine 15.
Scheme 5: Synthesis of compound 22.
Beilstein J. Org. Chem. 2010, 6, No. 6, doi:10.3762/bjoc.6.6
Graphical Abstract
Scheme 1: AlCl3-mediated reaction between amyl chloride and benzene as developed by Friedel and Crafts.
Figure 1: Most often used metal salts for catalytic FC alkylations and hydroarylations of arenes.
Figure 2: 1,1-diarylalkanes with biological activity.
Scheme 2: Alkylating reagents and side products produced.
Scheme 3: Initially reported TeCl4-mediated FC alkylation of 1-penylethanol with toluene.
Scheme 4: Sc(OTf)3-catalyzed FC benzylation of arenes.
Scheme 5: Reductive FC alkylation of arenes with arenecarbaldehydes.
Scheme 6: Iron(III)-catalyzed FC benzylation of arenes and heteroarenes.
Scheme 7: A gold(III)-catalyzed route to beclobrate.
Scheme 8: Catalytic FC-type alkylations of 1,3-dicarbonyl compounds.
Scheme 9: Iron(III)-catalyzed synthesis of phenprocoumon.
Scheme 10: Bi(OTf)3-catalyzed FC alkylation of benzyl alcohols developed by Rueping et al.
Scheme 11: (A) Bi(OTf)3-catalyzed intramolecular FC alkylation as an efficient route to substituted fulvenes. ...
Scheme 12: FC-type glycosylation of 1,2-dimethylindole and trimethoxybenzene.
Scheme 13: FC alkylation with highly reactive ferrocenyl- and benzyl alcohols. The reaction proceeds even with...
Scheme 14: Reductive FC alkylation of arenes with benzaldehyde and acetophenone catalyzed by the Ir-carbene co...
Scheme 15: Formal synthesis of 1,1-diarylalkanes from benzyl alcohols and styrenes.
Scheme 16: (A) Mo-catalyzed hydroarylation of styrenes and cyclohexenes. (B) Hydroalkylation–cyclization casca...
Scheme 17: Bi(III)-catalyzed hydroarylation of styrenes with arenes and heteroarenes.
Scheme 18: BiCl3-catalyzed ene/FC alkylation reaction cascade – A fast access to highly arylated dihydroindene...
Scheme 19: Au(I)/Ag(I)-catalyzed hydroarylation of indoles with styrenes, aliphatic and cyclic alkenes.
Scheme 20: First transition-metal-catalyzed ortho-hydroarylation developed by Beller et al.
Scheme 21: (A) Ti(IV)-mediated rearrangement of an N-benzylated aniline to the corresponding ortho-alkylated a...
Scheme 22: Dibenzylation of aniline gives potentially useful amine-based ligands in a one-step procedure.
Scheme 23: FC-type alkylations with allyl alcohols as alkylating reagents – linear vs. branched product format...
Scheme 24: (A) First catalytic FC allylation and cinnamylation using allyl alcohols and its derivatives. (B) E...
Scheme 25: FC allylation/cyclization reaction yielding substituted chromanes.
Scheme 26: Synthesis of (all-rac)-α-tocopherol utilizing Lewis- and strong Brønsted-acids.
Scheme 27: Au(III)-catalyzed cinnamylation of arenes.
Scheme 28: “Exhaustive” allylation of benzene-1,3,5-triol.
Scheme 29: Palladium-catalyzed allylation of indole.
Scheme 30: Pd-catalyzed synthesis of pyrroloindoles from L-tryptophane.
Scheme 31: Ru(IV)-catalyzed allylation of indole and pyrroles with unique regioselectivity.
Scheme 32: Silver(I)-catalyzed intramolecular FC-type allylation of arenes and heteroarenes.
Scheme 33: FC-type alkylations of arenes using propargyl alcohols.
Scheme 34: (A) Propargylation of arenes with stoichiometric amounts of the Ru-allenylidene complex 86. (B) Fir...
Scheme 35: Diruthenium-catalyzed formation of chromenes and 1H-naphtho[2,1-b]pyrans.
Scheme 36: Rhenium(V)-catalyzed FC propargylations as a first step in the total synthesis of podophyllotoxin, ...
Scheme 37: Scandium-catalyzed arylation of 3-sulfanyl- and 3-selanylpropargyl alcohols.
Scheme 38: Synthesis of 1,3-diarylpropynes via direct coupling of propargyl trichloracetimidates and arenes.
Scheme 39: Diastereoselective substitutions of benzyl alcohols.
Scheme 40: (A) First diastereoselective FC alkylations developed by Bach et al. (B) anti-Selective FC alkylati...
Scheme 41: Diastereoselective AuCl3-catalyzed FC alkylation.
Scheme 42: Bi(OTf)3-catalyzed alkylation of α-chiral benzyl acetates with silyl enol ethers.
Scheme 43: Bi(OTf)3-catalyzed diastereoselective substitution of propargyl acetates.
Scheme 44: Nucelophilic substitution of enantioenriched ferrocenyl alcohols.
Scheme 45: First catalytic enantioselective propargylation of arenes.
Beilstein J. Org. Chem. 2009, 5, No. 33, doi:10.3762/bjoc.5.33
Graphical Abstract
Scheme 1: Aziridine containing natural products.
Scheme 2: Mitomycin structures and nomenclature.
Scheme 3: Base catalysed epimerization of mitomycin B.
Scheme 4: Biosynthesis of mitomycin C (MMC) 7.
Scheme 5: Mode of action of mitomycin C.
Scheme 6: The N–C3–C9a disconnection.
Scheme 7: Danishefsky’s Retrosynthesis of mitomycin K.
Scheme 8: Hetero Diels–Alder reaction en route to mitomycins.
Scheme 9: Nitroso Diels–Alder cycloaddition.
Scheme 10: Frank azide cycloadddition.
Scheme 11: Final steps of mitomycin K synthesis. aPDC, DCM; bPhSCH2N3, PhH, 80 °C; cL-selectride, THF, −78 °C; ...
Scheme 12: Naruta–Maruyama retrosynthesis.
Scheme 13: Synthesis of a leucoaziridinomitosane by nitrene cycloaddition. aAlCl3-Et2O; bNaH, ClCH2OMe; cn-BuL...
Scheme 14: Thermal decomposition of azidoquinone 51.
Scheme 15: Diastereoselectivity during the cycloaddition.
Scheme 16: Oxidation with iodo-azide.
Scheme 17: Williams’ approach towards mitomycins.aDEIPSCl, Imidazole, DCM; bPd/C, HCO2NH4, MeOH; cAllocCl, NaH...
Scheme 18: Synthesis of pyrrolidones by homoconjugate addition.
Scheme 19: Homoconjugate addition on the fully functionalized substrate.
Scheme 20: Introduction of the olefin.
Scheme 21: Retrosynthesis of N–C9a, N–C3 bond formation.
Scheme 22: Synthesis of the pyrrolo[1,2]indole 82 using N-PSP activation.aAc2O, Py; bAc2O, Hg(OAc)2, AcOH, 90%...
Scheme 23: Synthesis of an aziridinomitosane. am-CPBA, DCM then iPr2NH, CCl4 reflux; bK2CO3, MeOH; cBnBr, KH; d...
Scheme 24: Oxidation products of a leucoaziridinomitosane obtained from a Polonovski oxidation.
Scheme 25: Polonovski oxidation of an aziridinomitosane. am-CPBA; bPd/C, H2; cDimethoxypropane, PPTS.
Scheme 26: The C1–C9a disconnection.
Scheme 27: Ziegler synthesis of desmethoxymitomycin A.aIm2C=O, THF; bNH3; cTMSOTf, 2,6-di-tert-butylpyridine, ...
Scheme 28: Transformation of sodium erythorbate.aTBDMSCl; bNaN3; cPPh3; d(Boc)2O, DMAP; eTBAF; fTf2O, Pyr.
Scheme 29: Formation of C9,C10-unsaturation in the mitomycins. am-CPBA, DCM; bO3, MeOH; cMe2S; dKHMDS, (EtO)3P...
Scheme 30: Fragmentation mechanism.
Scheme 31: Michael addition-cyclisation.
Scheme 32: SmI2 8-endo-dig cyclisation.
Scheme 33: Synthesis of pyrrolo[1,2-a]indole by 5-exo-dig radical cyclization.
Scheme 34: The C9–C9a disconnection.
Scheme 35: Intramolecular nitrile oxide cycloaddition.
Scheme 36: Regioselectivity of the INOC.
Scheme 37: Fukuyama’s INOC strategy.
Scheme 38: Synthesis of a mitosane core by rearrangement of a 1-(1-pyrrolidinyl)-1,3-butadiene.
Scheme 39: Sulikowski synthesis of an aziridinomitosene. aPd(Tol3P)2Cl2, Bu3SnF, 140; bH2, Pd/C; cTFAA, Et3N; d...
Scheme 40: Enantioselective carbene insertion.
Scheme 41: Parson’s radical cyclization.
Scheme 42: Cha’s mitomycin B core synthesis.
Scheme 43: The N-aromatic disconnection.
Scheme 44: Kishi retrosynthesis.
Scheme 45: Kishi synthesis of a starting material. aallyl bromide, K2CO3, acetone, reflux; bN,N-Dimethylanilin...
Scheme 46: Kishi synthesis of MMC 7. aLDA, THF, −78 °C then PhSeBr, THF, −78 °C; bH2O2, THF-EtOAc; cDIBAL, DCM...
Scheme 47: Acid catalyzed degradation of MMC 7.
Scheme 48: In vivo formation of apomitomycin B.
Scheme 49: Advanced intermediate for apomitomycin B synthesis.
Scheme 50: Remers synthesis of a functionalized mitosene. aTMSCl, Et3N, ZnCl2 then NBS; bAcOK; cNH2OH; dPd/C, H...
Scheme 51: Coleman synthesis of desmethoxymitomycin A. aSnCl2, PhSH, Et3N, CH3CN; bClCO2Bn, Et3N; cPPh3, DIAD,...
Scheme 52: Transition state and pyrrolidine synthesis.
Scheme 53: Air oxidation of mitosanes and aziridinomitosanes.
Scheme 54: The C9-aromatic disconnection.
Scheme 55: Synthesis of the aziridine precursor. aLHMDS, THF; bNaOH; c(s)-α-Me-BnNH2, DCC, HOBT; dDIBAL; eK2CO3...
Scheme 56: Synthesis of 206 via enamine conjugate addition.
Scheme 57: Rapoport synthesis of an aziridinomitosene.
Scheme 58: One pot synthesis of a mitomycin analog.
Scheme 59: Synthesis of compound 218 via intramolecular Heck coupling. aEtMgCl, THF, then 220; bMsCl, Et3N; cN...
Scheme 60: Elaboration of indole 223. aEt3N, Ac2O; bAcOH; cSOCl2, Et3N; dNaN3, DMF; eH2SO4, THF; fK2CO3, MeOH; ...
Scheme 61: C9-C9a functionalization from indole.
Scheme 62: Synthesis of mitomycin K. a2 equiv. MoO5.HMPA, MeOH; bPPh3, Et3N, THF-H2O; cMeOTf, Py, DCM; dMe3SiCH...
Scheme 63: Configurational stability of mitomycin K derivatives.
Scheme 64: Epimerization of carbon C9a in compound 227b.
Scheme 65: Corey–Chaykovsky synthesis of indol 235.
Scheme 66: Cory intramolecular aza-Darzens reaction for the formation of aziridinomitosene 239.
Scheme 67: Jimenez synthesis of aziridinomitosene 242.
Scheme 68: Von Braun opening of indoline 244.
Scheme 69: C9a oxidation of an aziridinomitosane with DDQ/OsO4.
Scheme 70: Synthesis of epi-mitomycin K. aNaH, Me2SO4; bH2, Pd/C; cMitscher reagent [165]; d[(trimethylsilyl)methyl...
Scheme 71: Mitomycins rearrangement.
Scheme 72: Fukuyama’s retrosynthesis.
Scheme 73: [2+3] Cycloaddition en route to isomitomycin A. aToluene, 110 °C; bDIBAL, THF, −78 °C; cAc2O, Py.; d...
Scheme 74: Final steps of Fukuyama’s synthesis.
Scheme 75: “Crisscross annulation”.
Scheme 76: Synthesis of 274; the 8-membered ring 274 was made using a crisscross annulation. a20% Pd(OH)2/C, H2...
Scheme 77: Conformational analysis of compound 273 and 275.
Scheme 78: Synthesis of a mitomycin analog. aNa2S2O4, H2O, DCM; bBnBr (10 equiv), K2CO3, 18-crown-6 (cat.), TH...
Scheme 79: Vedejs retrosynthesis.
Scheme 80: Formation of the azomethine ylide.
Scheme 81: Vedejs second synthesis of an aziridinomitosene. aDIBAL; bTPAP, NMO; c287; dTBSCl, imidazole.
Scheme 82: Trityl deprotection and new aziridine protecting group 300.
Scheme 83: Ene reaction towards benzazocinones.
Scheme 84: Benzazocenols via homo-Brook rearrangement.
Scheme 85: Pt-catalyzed [3+2] cycloaddition.
Scheme 86: Carbonylative lactamization entry to benzazocenols. aZn(OTf)2, (+)-N-methylephedrine, Et3N, TMS-ace...
Scheme 87: 8 membered ring formation by RCM. aBOC2O, NaHCO3; bTBSCl, Imidazole, DMF; callyl bromide, NaH, DMF; ...
Scheme 88: Aziridinomitosene synthesis. aTMSN3; bTFA; cPOCl3, DMF; dNaClO2, NaH2PO4, 2-methyl-2-butene; eMeI, ...
Scheme 89: Metathesis from an indole.
Scheme 90: Synthesis of early biosynthetic intermediates of mitomycins.
Beilstein J. Org. Chem. 2009, 5, No. 10, doi:10.3762/bjoc.5.10
Graphical Abstract
Scheme 1: 1a n = 8 R1 = H; 1b n = 10 R1 = H; 1c n = 12 R1 = H; 1d n = 14 R1 = H; 1e n = 8 R1 = C2H5; 1f n = 1...
Figure 1: Effect of different methods using 20 mg of enzyme at 60 °C; Method A: conventional method, Method B...
Figure 2: Effect of the temperature using equimolar ratio and 20 mg of enzyme.